10-Q: Encompass Health Reports Strong Q2 Growth, Boosts Dividend

Encompass Health Corporation announced significant revenue and earnings growth for Q2 2025, driven by increased patient volumes and favorable pricing, alongside strategic expansion and a dividend increase.

Summary

• Net operating revenues increased by 12.0% to $1,457.7 million for the three months ended June 30, 2025, and by 11.3% to $2,913.1 million for the six months ended June 30, 2025, compared to the same periods in 2024.
• Net income attributable to Encompass Health rose 24.5% to $142.1 million for the three months ended June 30, 2025, and 29.6% to $293.6 million for the six months ended June 30, 2025.
• Diluted earnings per share increased to $1.39 for Q2 2025 from $1.12 for Q2 2024, and to $2.87 for the six months ended June 30, 2025, from $2.22 for the same period in 2024.
• Discharges grew by 7.2% for the three months and 6.8% for the six months ended June 30, 2025, with same-store discharges increasing by 4.7% and 4.5% respectively.
• Net patient revenue per discharge increased by 4.2% to $21,670 for Q2 2025 and 4.1% to $21,743 for the six months ended June 30, 2025.
• Occupancy percentage improved to 76.6% for Q2 2025 from 74.5% for Q2 2024, and to 77.4% for the six months ended June 30, 2025, from 75.0% for the same period in 2024.
• The company acquired 51% of a 54-bed inpatient rehabilitation unit in Fort Myers, Florida, in May 2025, and opened new hospitals in Athens, Georgia (40 beds, March 2025) and Fort Myers, Florida (60 beds, May 2025).
• An additional 51 new beds were added to existing hospitals during the period.
• The board of directors approved an increase in the quarterly cash dividend to $0.19 per share, payable on October 15, 2025.
• Approximately $433 million remained under the $500 million common stock repurchase authorization as of June 30, 2025, with $56.8 million in repurchases made during the six months ended June 30, 2025.
• The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, is expected to result in approximately $180 million in current deductions and $50 million in cash tax savings for 2025 due to bonus depreciation and R&D expensing provisions.
• The 2026 Final IRF Rule, effective October 1, 2025, will implement a net 2.6% market basket increase, with the company expecting a net increase of approximately 2.9% to its Medicare payment rates.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant increases in revenue, net income, and EPS, driven by volume growth and favorable pricing. Strategic expansion efforts are progressing, and the company is returning capital to shareholders through increased dividends and share repurchases. While regulatory challenges and staffing costs are acknowledged, management expresses confidence in its ability to adapt and grow, supported by a strong balance sheet and positive demographic trends. The overall tone is highly positive, backed by solid financial metrics.

Positives

• Strong revenue growth of 12.0% for the quarter and 11.3% for the six months, driven by volume and pricing increases.
• Significant increase in net income attributable to Encompass Health, up 24.5% for the quarter and 29.6% for the six months.
• Improved diluted EPS, rising from $1.12 to $1.39 for the quarter and $2.22 to $2.87 for the six months.
• Robust discharge growth of 7.2% for the quarter and 6.8% for the six months, including strong same-store growth.
• Increased net patient revenue per discharge by 4.2% for the quarter and 4.1% for the six months.
• Improved occupancy rates, indicating efficient utilization of hospital capacity.
• Successful strategic expansion with the acquisition of a 54-bed unit and the opening of two new hospitals, plus 51 new beds added to existing facilities.
• Reduction in revenue reserves related to bad debt from 2.9% to 2.0% of net operating revenues, primarily due to fewer medical necessity claim review audits.
• Decrease in interest expense by 11.4% for the quarter and 10.5% for the six months, contributing to higher profitability.
• Anticipated cash tax savings of approximately $50 million in 2025 due to provisions in the One Big Beautiful Bill Act (OBBBA).
• Board-approved increase in quarterly dividend to $0.19 per share, demonstrating confidence in future cash flows and commitment to shareholder returns.
• Substantial remaining capacity of approximately $433 million under the common stock repurchase authorization, providing flexibility for future shareholder returns.
• Positive outlook on Medicare payment rates with an expected net increase of approximately 2.9% effective October 1, 2025, under the 2026 Final IRF Rule.

Negatives

• Salaries and benefits increased by 9.6% for the quarter and 8.3% for the six months, reflecting higher labor costs and increased patient volumes.
• Other operating expenses increased by 12.6% for the quarter and 9.5% for the six months, primarily due to increased provider taxes and development activities.
• General and administrative expenses increased by 17.6% for the quarter and 10.9% for the six months, driven by mark-to-market adjustments on non-qualified deferred compensation, higher incentive compensation, benefits, and salaries.
• Net cash used in investing activities increased to $323.9 million for the six months ended June 30, 2025, from $288.1 million in the prior year, primarily due to increased capital expenditures.
• Net cash used in financing activities significantly increased to $220.6 million for the six months ended June 30, 2025, from $90.2 million in the prior year, mainly due to higher stock repurchases and net debt payments.
• The company's IRFs in Alabama did not achieve the required claim validation rates (85% for the second cycle, 90% for the third cycle) under CMS's Review Choice Demonstration (RCD), raising concerns about future collectability of Medicare claims.
• The company believes many non-affirmations in RCD were based on improper standards, indicating ongoing regulatory challenges and potential disputes with CMS.

Risks

• Reductions or delays in, or suspension of, reimbursement for services by governmental or private payors, including inability to obtain and retain favorable arrangements with third-party payors.
• Restrictive interpretations of regulations governing Medicare reimbursable claims.
• Audits by governmental agencies and contractors, which may lead to assertions of overpayment or improper claims, potentially requiring refunds and increased defense costs.
• The use of statistical sampling and extrapolation by governmental agencies and contractors, which may substantially expand claims of overpayment or noncompliance.
• Substantive and procedural deficiencies in the administrative appeals process for denied Medicare reimbursement claims, potentially delaying or reducing reimbursement.
• Efforts to reduce payments to healthcare providers by third-party payors and conveners.
• Changes in payor mix or patient acuity that could reduce revenues or profitability.
• Significant reforms or limitations to Medicaid at federal and state levels, including those reducing coverage or provider reimbursement.
• Changes in healthcare industry rules and regulations, including those related to healthcare reform and deficit reduction (e.g., IRF Review Choice Demonstration, re-basing of payment systems, site neutral payments, case-mix weightings).
• Alternative payment models and value-based purchasing initiatives that could decrease patient volumes and reimbursement rates or increase costs.
• Failure to comply with extensive and frequently changing laws and regulations applicable to healthcare providers, leading to penalties, significant costs, or operational changes.
• Inability to maintain proper local, state, and federal licensing, including compliance with Medicare conditions of participation and provider enrollment requirements.
• Incidents affecting the proper operation, availability, or security of information systems, including patient information, or business continuity, leading to substantial losses.
• Adverse outcomes of various lawsuits, claims, and legal or regulatory proceedings, including undisclosed qui tam suits.
• Inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with growth strategy.
• Inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with staffing shortages and potential union activity, leading to increased staffing costs.
• Competitive pressures in the healthcare industry, including from large acute-care hospitals.
• Medicare quality reporting requirements adversely affecting operating costs or Medicare reimbursement.
• Inability to provide a consistently high quality of care, as represented in Medicare-published metrics.
• Inability to maintain or develop relationships with patient referral sources or managed care payors.
• Operational or financial challenges experienced by acute-care hospitals participating in joint ventures.
• A pandemic, epidemic, or other widespread outbreak of an infectious disease or public health crisis, and governmental responses, potentially decreasing patient volumes, pricing, and revenues, or leading to staffing/supply shortages.
• Regional (particularly Texas or Florida) or global socio-political, weather, or other catastrophic events disrupting business.
• Regulatory and other efforts to promote a transition to a lower-carbon economy, resulting in operational and financial challenges.
• Inability to maintain infectious disease prevention and control efforts.
• Debt and associated restrictive covenants, which could have negative consequences for the business and limit execution of business plans.
• The price of common stock adversely affecting willingness and ability to repurchase shares.
• Inability or unwillingness to continue to declare and pay dividends on common stock.
• General conditions in the economy and capital markets, including inflation, armed conflict, governmental impasse over federal budget/debt ceiling, international trade war, or sovereign debt crisis.

Future Outlook

The company remains optimistic about its intermediate and long-term prospects, citing demographic trends such as population aging, which is expected to increase demand for inpatient rehabilitation services. The number of Medicare enrollees (65 and older) is projected to grow approximately 3% per year, reaching 71 million by 2030, with the 75 and older population growing at about 4% per year through 2030. The company believes its strengths in clinical outcomes, cost-effectiveness, financial strength, and technology application position it to adapt and succeed in a dynamic, highly regulated healthcare industry. It plans to continue its growth strategy through de novo hospitals and bed additions, supported by a flexible capital structure with no significant debt maturities until 2028 and ample liquidity.

Management Comments

• "We remain optimistic regarding the intermediate and long-term prospects of our business."
• "Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide."
• "We believe the demand for the services we provide will continue to increase as the U.S. population ages."
• "We are committed to delivering high-quality, cost-effective patient care."
• "We believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology."
• "We believe our competitive strengths... give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs."
• "Our goal is to position the Company in a prudent manner to be responsive to industry shifts."
• "We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis."
• "We have been disciplined in creating a capital structure that is flexible with no significant debt maturities until 2028."
• "We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through de novo hospitals and bed additions."
• "We have a proven track record of working through difficult operating environments, and we believe in our ability to overcome current and future challenges."

Industry Context

The healthcare industry is highly regulated and undergoing a transformation towards coordinated care delivery and payment models, with uncertain timing and extent. Encompass Health, as the nation's largest owner and operator of inpatient rehabilitation hospitals, is significantly exposed to Medicare regulations and reimbursement changes. The company benefits from strong demographic tailwinds, particularly the aging U.S. population, which is expected to drive increasing demand for rehabilitative services. The industry faces ongoing challenges such as staffing shortages, increased labor costs, and competitive pressures from acute-care hospitals and other post-acute providers. Regulatory initiatives like CMS's Review Choice Demonstration (RCD) add complexity and uncertainty to reimbursement processes.

Comparison to Industry Standards

• Encompass Health is the nation's largest owner and operator of inpatient rehabilitation hospitals (IRFs) in terms of patients treated, revenues, and number of hospitals, indicating a leading market position.
• The company differentiates itself from competitors based on the quality of its clinical outcomes, cost-effectiveness, financial strength, and extensive application of technology, suggesting a competitive advantage in these areas.
• The company's ability to achieve significant revenue and net income growth, coupled with improved occupancy rates and net patient revenue per discharge, suggests strong operational performance relative to the broader, often challenging, healthcare services sector.
• The company's proactive approach to strategic expansion through de novo developments and bed additions aligns with growth strategies seen in other successful healthcare providers seeking to capitalize on demographic trends.

Legal Proceedings

• The company is subject to regulatory and other governmental audits and investigations, as well as various legal actions, proceedings, and claims, including employment and personal injury claims.
• Resolution of these matters could materially and adversely affect financial position, results of operations, and cash flows.
• The company may be subject to undisclosed qui tam lawsuits under the False Claims Act, which can involve significant monetary damages, fines, and attorneys' fees.
• The company routinely conducts audits and reviews of its billing systems and regulatory compliance, leading to disclosures of suspected over-payments to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare & Medicaid Services.

Stakeholder Impact

• Shareholders: Positive impact due to increased net income, higher diluted EPS, increased quarterly dividends, and ongoing share repurchase program.
• Employees: Increased salaries and benefits, but also face challenges related to staffing shortages and competition for qualified personnel.
• Patients: Benefit from the company's focus on providing high-quality, cost-effective inpatient rehabilitation services and expansion of hospital capacity.
• Payors (e.g., Medicare, Medicare Advantage, Managed Care): Impacted by changes in reimbursement rates and regulatory requirements, such as the 2026 Final IRF Rule and the Review Choice Demonstration (RCD) program.
• Creditors: The company maintains a flexible capital structure with no significant debt maturities until 2028 and ample availability under its revolving credit facility, indicating strong financial health and ability to service debt.

Next Steps

• Continue development of new inpatient rehabilitation hospitals and expansion of existing capacity, with several projects slated for 2025, 2026, and 2027.
• Evaluate the tax and healthcare-related provisions of the One Big Beautiful Bill Act (OBBBA) and any related federal and state regulatory actions as they develop.
• Engage with the Medicare Administrative Contractor (MAC) and CMS to ensure the Review Choice Demonstration (RCD) review process is consistent with existing rules, regulations, and statutes, particularly concerning non-affirmations in Alabama.
• Continue to declare and pay quarterly cash dividends, with the next dividend of $0.19 per share payable on October 15, 2025.
• Execute further common stock repurchases under the remaining $433 million authorization, subject to market conditions and compliance with debt covenants.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance, with robust growth in net operating revenues, net income, and EPS. Key operational metrics like discharges and occupancy rates show strong underlying business health. The company is actively expanding its footprint through new hospital developments and bed additions, capitalizing on favorable demographic trends. Furthermore, the increase in the quarterly dividend and the substantial remaining share repurchase authorization signal a strong commitment to shareholder returns. While regulatory risks and labor cost pressures exist, the company's proven track record, strong balance sheet, and proactive management of these challenges suggest continued positive momentum, making it an attractive investment.

Keywords

Inpatient Rehabilitation, Healthcare Services, SEC Filing, Quarterly Report, Financial Performance, Hospital Operations, Medicare Reimbursement, Patient Volume, Earnings Per Share, Dividend, Stock Repurchase, Capital Expenditures, Regulatory Compliance, Staffing Shortages, Joint Ventures, OBBBA, IRF Rule, Review Choice Demonstration